Progenitor endothelial cell capturing with a drug eluting implantable medical device

• US 8,088,060 B2
• Filed: 11/15/2006
• Issued: 01/03/2012
• Est. Priority Date: 03/15/2000
• Status: Expired due to Term

• Current Assignee: OrbusNeich Medical Pte Ltd
• Original Assignee: Orbusneich Medical Incorporated (Orbusneich Medical)
• Inventors: Cottone, Robert John Jr., Yoklavich, Margaret, Parker, Sherry
• Primary Examiner(s): Schultz, Doug
• Application Number:
  US11/560,353
• Publication Number:
  US 20070123977A1
• Time in Patent Office: 1,875 Days
• Field of Search: None
• US Class Current: 600/36
• CPC Class Codes: A61F 2/91 made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
• CPC Class Codes: A61L 2300/256 Antibodies, e.g. immunoglobulins, vaccines
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

Claims

1. An implantable medical device having a lumen, a luminal surface, a tissue-contacting surface, and a coating;

said coating comprising;

one or more covalently bound luminal surface layers of a matrix comprising a natural fiber selected from elastin, tropoelastin;

cross-linked tropoelastin or combinations thereof;

a tissue-contacting biodegradable and biocompatible synthetic polymer layer comprising a therapeutically effective amount of one or more intimal hyperplasia inhibitory pharmaceutical substances, and one or more pharmaceutically acceptable carriers on said tissue-contacting surface; and

a therapeutically effective amount of a ligand selected from an antibody, an antibody fragment and combinations thereof,

said ligand being covalently attached to said matrix and configured specifically to bind in situ to a cell surface antigen or cell membrane molecule comprising CD133, CD45, CD34, CD31, CD14, CDw90, CD117, VEGFR-1, VEGFR-2, Muc-I8 (CD146), CD130, stem cell antigen (Sca-1), stem cell factor 1 (SCF/c-Kit ligand), Tie-2, or MHC-H-2Kk of circulating autologous endothelial progenitor cells in peripheral blood for in vivo capture and proliferation of said endothelial progenitor cells to form a functional endothelial layer on said luminal surface of the implantable medical device, in situ.

2. The implantable medical device of claim 1, wherein the medical device is a stent.

3. The implantable medical device of claim 2, wherein the ligand has specificity to and binds selectively an antigen or cell membrane molecule selected from the group consisting of CD133, CD45, CD34, CD31, CD14, CDw90, CD117, VEGFR-1, VEGFR-2, Muc-I8 (CD146), CD130, stem cell antigen (Sca-1), stem cell factor 1 (SCF/c-Kit ligand), Tie-2, and MHC-H-2Kk.

4. The implantable medical device of claim 1, wherein the one or more pharmaceutical substance(s) comprise immunosuppressive agents.

5. The implantable medical device of claim 1, wherein the coating further comprises one or more barrier layers in between said one or more layers of matrix comprising said pharmaceutical substances.

6. The implantable medical device of claim 5, wherein the barrier layer comprise a biodegradable material comprising poly(D,L-lactide-co-glyclide).

7. The implantable medical device of claim 6, wherein the biodegradable material is a suitable biodegradable polymer selected from the group consisting of polyesters, polycarboxylic acid, polyanhydrides;

polyarthoesters;

poly-amino acids;

polyethylene oxide;

polyphosphazenes;

polylactic acid, polyglycolic acid;

polydioxanone;

polypropylene fumarate;

polydepsipeptides;

polycaprolactone, lactide-co-glyclide), poly(D,L-lactide-co-caprolactone);

poly polycaprolactone co-butylacrylate;

polyhydroxybutyrate valerate;

polycarbonates;

calcium phosphates;

polyglycosaminoglycans;

proteins and polypeptides.

8. The implantable medical device of claim 7, wherein the polylactide and polyglycic acid copolymers are selected from the group consisting of poly(L-lactic acid) (PLLA), poly(D,L,-lactide), poly(lactic acid-co-glycolic acid), 50/50 (D,L-lactide-co-glycolide), and mixtures of poly (D,L-lactide-co-caprolactone).

14. The implantable medical device of claim 1, wherein the one or more pharmaceutical substance(s) is/are selected from the group consisting of antibiotics/antimicrobials, antiproliferative agents, antineoplastic agents, antioxidants, endothelial cell growth factors, smooth muscle cell growth and/or migration inhibitors, thrombin inhibitors, immunosuppressive agents, anti-platelet aggregation agents, collagen synthesis inhibitors, therapeutic antibodies, nitric oxide donors, antisense oligonucleotides, wound healing agents, therapeutic gene transfer constructs, peptides, proteins, extracellular matrix components, vasodialators, thrombolytics, anti-metabolites, growth factor agonists, antimitotics, steroids, steroidal antiinflammatory agents, chemokines, proliferator-activated receptor-gamma agonists, nonsterodial antiinflammatory agents, angiotensin converting enzyme (ACE) inhibitors, free radical scavengers, inhibitors of the CX3CR1 receptor and anti-cancer chemotherapeutic agents.

15. The medical device of claim 1, wherein the one or more pharmaceutical substance(s) is/are selected from the group consisting of cyclosporin A, mycophenolic acid, mycophenolate mofetil acid, rapamycin, rapamycin derivatives, azathioprene, tacrolimus, tranilast, dexamethasone, corticosteroid, everolimus, retinoic acid, vitamin E, rosiglitazone, simvastatins, fluvastatin, estrogen, 17β

-estradiol, dihydroepiandrosterone, testosterone, puerarin, platelet factor 4, basic fibroblast growth factor, fibronectin, butyric acid, butyric acid derivatives, paclitaxel, paclitaxel derivatives and probucol.

9. A stent having tissue contacting surface, a lumen, a luminal surface, and a coating;

said coating comprising;

a layered matrix comprising a natural fiber selected from tropoelastin;

cross-linked tropoelastin and combinations thereof,

a therapeutically effective amount of one or more antibody, antibody fragment or combinations thereof, covalently attached to said layered matrix and specifically configured to bind selectively in situ to a cell surface antigen or cell surface membrane molecule, CD34, of circulating autologous endothelial progenitor cells in peripheral blood for capture and proliferation in vivo to form a confluent endothelial cell layer on said luminal surface of the device in less than 72 hours; and

one or more biodegradable barrier layers situated within said layered matrix, said biodegradable barrier layers comprising a therapeutically effective amount of one or more pharmaceutical substances and one or more pharmaceutically acceptable carriers for release to adjacent vascular tissue.

10. The stent of claim 9, wherein the biodegradable material is a suitable biodegradable polymer selected from the group consisting of polyesters, polycarboxylic acid, polyanhydrides;

polyarthoesters;

poly-amino acids;

polyethylene oxide;

polyphosphazenes;

polylactic acid, polyglycolic acid;

polydioxanone;

polypropylene fumarate;

polydepsipeptides;

polycaprolactone, poly(D,L-lactide-co-caprolactone);

poly polycaprolactone co-butytacrylate;

polyhydroxybutyrate valerate;

polycarbonates;

calcium phosphates;

polyglycosaminoglycans;

proteins and polypeptides.

11. The stent of claim 10, wherein the polylactide and polyglycic acid copolymers are selected from the group consisting of poly(D,L-lactide-co-glycolic acid), and poly(D,L-lactide-co-caprolactone).

12. The stent of claim 9, wherein the pharmaceutically acceptable substances comprise cytostatic or cytotoxic agents.

13. The stent of claim 9, wherein the pharmaceutically acceptable substances comprise immunosuppressive agents.

16. The medical device of claim 9, wherein the one or more pharmaceutical substances comprise rapamycin, rapamycin derivatives, paclitaxel, paclitaxel derivatives, or estradiol.

17. A vascular stent for in situ capture of circulating progenitor cells and therapeutically effective drug release, comprising:

a tissue-adjacent surface, a luminal surface, and a multilayer coating;

the multilayer coating comprising a luminal surface matrix consisting of covalently bound elastin, tropoelastin, cross-linked tropoelastin, or combinations thereof to which matrix one or more antibodies or antibody fragments are covalently bound, specifically directed against a surface antigen selected from CD34, CD31, and CD133 of circulating native or genetically engineered progenitor cells; and

the multilayer coating comprising one or more tissue-adjacent biodegradable synthetic polymer layers comprising one or more intimal hyperplasia inhibitory pharmaceutical substances.